Evaluation of response to chemotherapy in patients affected with non-small cell lung cancer by means of three tumour markers elaborated by discriminant analysis

Chemotherapy is the most effective treatment for inoperable patients (70%) affected with non-small cell lung cancer (NSCLC). The early detection of tumour progression is mandative in order to promptly shift these patients towards salvage or supportive therapy. The present authors investigated the cl...

Full description

Saved in:
Bibliographic Details
Published in:Respiratory medicine 1997-07, Vol.91 (6), p.361-367
Main Authors: Paone, G., De Angelis, G., Greco, S., Portalone, L., De Marchis, L., Galluccio, G., Taglienti, A., Bisetti, A., Ameglio, F.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Algorithms
Biological and medical sciences
Biomarkers, Tumor - blood
Carcinoembryonic Antigen - blood
Carcinoma, Non-Small-Cell Lung - blood
Carcinoma, Non-Small-Cell Lung - drug therapy
Discriminant Analysis
Disease Progression
Female
Humans
Lung Neoplasms - blood
Lung Neoplasms - drug therapy
Male
Medical sciences
Middle Aged
Phosphopyruvate Hydratase - blood
Pneumology
Tissue Polypeptide Antigen - blood
Treatment Outcome
Tumors of the respiratory system and mediastinum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chemotherapy is the most effective treatment for inoperable patients (70%) affected with non-small cell lung cancer (NSCLC). The early detection of tumour progression is mandative in order to promptly shift these patients towards salvage or supportive therapy. The present authors investigated the clinical value of a panel of tumour markers, elaborated by means of discriminant analysis, as a follow-up indicator for the detection of tumour progression. The serum levels of tissue polypeptide antigen (TPA), CYFRA-21.1, neuron-specific enolase (NSE) and carcinoembryonic antigen (CEA) were determined before chemotherapy and after three cycles of treatment. Discriminant analysis generated a formula (canonic variable) which correctly classified the 87·8% of the 74 subjects (86·1% of the 36 progressive diseases and 89·5% of 38 non-progressive diseases). This approach produces an algorithm able to calculate a progression score in NSCLC patients which can be helpful for following-up care and therapy control of these patients.
ISSN:0954-6111
1532-3064
DOI:10.1016/S0954-6111(97)90063-9